ImmuPharma (LON:IMM) Trading Up 79.2% – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report) shares rose 79.2% on Thursday . The stock traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.15 ($0.03). Approximately 21,651,871 shares changed hands during mid-day trading, an increase of 379% from the average daily volume of 4,518,033 shares. The stock had previously closed at GBX 1.20 ($0.01).

ImmuPharma Stock Up 75.0 %

The business has a 50-day simple moving average of GBX 1.36 and a 200-day simple moving average of GBX 1.63. The stock has a market cap of £8.75 million, a P/E ratio of -210.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Further Reading

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.